Finnrick Analytics
Finnrick.com
Austin, TX

Project 135194
Lab # 127328
Date Rec'd 7/15/2025
Report Issued 7/25/2025

Project
Sample TIRZEPATIDE 40 mg 715F8DEF355E-1-3

Certificate of Analysis

Analyte	Result	Units	Method	Date	% of Label
Peptide Analysis					
Purity by area	99.92	%	HPLC-UV/MS	22-Jul-25	
Purity by mass	41.1	mg	HPLC-UV/MS	22-Jul-25	102.84
Spectral identification	Confirmed		HPLC-UV/MS	22-Jul-25	

The data presented are from the analysis of the sample shown and meet Krause Analytical internal quality assurance criteria unless otherwise flagged.
Methods shown reference current Krause Analytical SOPs

Respectfully submitted,

Mark C. Krause
Laboratory Director

Lab #: 127328 TIRZEPATIDE 40 mg 715F8DEF355E-1-3

Chromatogram





Krause Analytical, LLC 8127 Mesa Drive Suite B-206 Austin, TX 78759

krause analytical

Spectra



Method Summary

- 2 mL of purified water is added to the lyophilized powder in the vial, and the contents mixed to dissolve the lyophilized powder.
- An aliquot is taken from the vial and diluted to contain approximately 500 mg/L of the peptide.
- The diluted sample is analyzed by HPLC-UV-MS.
- The mass spectrum obtained is compared to an authentic standard of the peptide for identification.
- The total area of all of the peaks in the chromatogram is calculated, and the area of the peak of the peptide is divided by the total area to obtain the purity by area value, reported in percent.
- The area of the peptide is compared to the area of the peptide peak in the known standard to obtain a concentration in the solution. This concentration is used to calculate the total mass of peptide in the vial, which is compared to the stated mass (label claim) and reported as both total mass in the vial and as a percent of the label claim.

Krause Analytical, LLC 8127 Mesa Drive Suite B-206 Austin, TX 78759